Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Drug-induced (medication-induced) depression in neurology practice

https://doi.org/10.14412/2074-2711-2021-2-104-110

Full Text:

Abstract

 One of the depression causes is the use of certain drugs, and in this case, the term drug-induced depression (DID), medication-induced or iatrogenic depression is used. Symptoms of DID are similar to those observed in patients with other types of depression. DID is also associated with morbidity and mortality. Its  development leads to a decrease in treatment adherence, and in  some cases, to discontinuation of drugs that have predictive value. The main point in the management of patients with DID is the rapid  detection and correction of symptoms and the application of prompt measures to prevent their development when prescribing  certain drugs. The features of the course of DID, pathogenetic  mechanisms and risk factors for its development, possible approaches to the treatment and prevention are discussed. 

About the Authors

E. Yu. Ebzeeva
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
Russian Federation

 2/1, Barrikadnaya St., Build. 1, Moscow 125993, Russia 



O. D. Ostroumova
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

 2/1, Barrikadnaya St., Build. 1, Moscow 125993, Russia 

 8, Trubetskaya St., Build. 2, Moscow 119991 Moscow, Russia 



S. V. Batyukina
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
Russian Federation

 2/1, Barrikadnaya St., Build. 1, Moscow 125993, Russia 



T. M. Ostroumova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

 8, Trubetskaya St., Build. 2, Moscow 119991 Moscow, Russia 



A. I. Kochetkov
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
Russian Federation

 2/1, Barrikadnaya St., Build. 1, Moscow 125993, Russia 



A. A. Kirichenko
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
Russian Federation

 2/1, Barrikadnaya St., Build. 1, Moscow 125993, Russia 



References

1. Oganov RG, Olbinskaya LI, Smulevich AB, et al. Depression and depressive spectrum disorders in general practice. The results of the KOMPAS program. Kardiologiya = Cardiology. 2004;(1):48-55 (In Russ.).

2. Parfenov VA. Depression in Depression in neurological practice and Paxil therapy. Atmosfera. Nevrologiya. 2004;(1):43-4 (In Russ.).

3. Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd ed. Bethesda, Md: American Society of Health-System Pharmacists; 2018. 1399 р.

4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.

5. Sychev DA, Zhuchkov AV, Tereshchenko OV, Ivashchenko DV. Tapering (deprescribing) of benzodiazepine tranquilizers. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(1):89-95. doi: 10.14412/2074-2711-2019-1-89-95 (In Russ.).

6. Kuehn BM. FDA warns of adverse events linked to smoking cessation drug and antiepileptics. JAMA. 2008 Mar 2;299(10):1121-2. doi: 10.1001/jama.299.10.1121

7. Warnock JK, Bundren JC. Anxiety and mood disorders associated with gonadotropin-releasing hormone agonist therapy. Psychopharmacol Bull. 1997;33(2):311-6.

8. Warnock JK, Bundren JC, Morris DW. Depressive mood symptoms associated with ovarian suppression. Fertil Steril. 2000 Nov;74(5):984-6. doi: 10.1016/s0015-0282(00)01607-1

9. Toren P, Dor J, Mester R, et al. Depression in women treated with a gonadotropin-releasing hormone agonist. Biol Psychol. 1996 Mar 1;39(5):378-82. doi: 10.1016/0006-3223(95)00473-4

10. Steingold KA, Cedars M, Lu JK, et al. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. Obstet Gynecol. 1987 Mar;69(3 Pt 1):403-11.

11. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 1992 Jan 4;339(8784):1-15.

12. Grigg JR. Prednisone mood disorder with associated catatatonia. Geriatr Psychiatry Neurol. Jan-Mar 1989;2(1):41-4. doi: 10.1177/089198878900200108

13. Available from: https://www.drugs.com (accessed:19.05.2020).

14. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975-82. doi: 10.1056/NEJMoa020047

15. Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol. 2001 Oct;45(4):515-9. doi: 10.1067/mjd.2001.117730

16. O'Donnell J. Overview of existing research and information linking isotretinoin (accutane), depression, psychosis, and suicide. Am J Ther. Mar-Apr 2003;10(2):148-59. doi: 10.1097/00045391-200303000-00012

17. Warnock JK, Bundren JC, Morris DW. Sertraline in the treatment of depression associated with gonadotropin-releasing hormone agonist therapy. Biol Psychiatry. 1998 Mar 15;43(6):464-5. doi: 10.1016/s0006-3223(97)00396-x

18. Tyuvina NA. The differential diagnosis and treatment of depressive disorders in menopausal women. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(1):66-71. doi: 10.14412/2074-2711-2011-137 (In Russ.).

19. Tyuvina NA, Voronina EO, Balabanova VV, Goncharova EM. The relationship and interaction of menstrual and generative function and depressive disorders in women. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(2):45-51. doi: 10.14412/2074-2711-2018-2-45-51 (In Russ.).

20. Patten SB, Williams JV, Love EJ. Self-reported depressive symptoms in association with medication exposures among medical inpatients: a cross-sectional study. Can J Psychiatry. 1995 Jun;40(5):264-9.

21. Gutierrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005 Dec 1;41(11):1648-53. doi: 10.1086/497835. Epub 2005 Oct 19.

22. Alzoubi KH, Khabour OF, Hassan RE, et al. The effect of genetic polymorphisms of RARA gene on the adverse effects profile of isotretinoin-treated acne patients. Int J Clin Pharmacol Ther. 2013 Aug;51(8):631-40. doi: 10.5414/CP201874

23. Mula M, Trimble MR, Sander JW. The role of hippocampal sclerosis in topiramate-related depression and cognitive deficits in people with epilepsy. Epilepsia. 2003 Dec;44(12):1573-7. doi: 10.1111/j.0013-9580.2003.19103.x

24. Mula M, Trimble MR, Lhatoo SD, Sander JW. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia. 2003 May;44(5):659-63. doi: 10.1046/j.1528-1157.2003.05402.x

25. Mula M, Hesdorffer DC, Trimble M, Sander JW. The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia. 2009 May;50(5):1072-6. doi: 10.1111/j.1528-1167.2008.01799.x. Epub 2008 Oct 24.

26. Galvao-de Almeida A, Quarantini LC, Tartaglioni AG, et al. Serotonin-1A receptor CC genotype is associated with persistent depression related to interferon-alpha in hepatitis C patients. Gen Hosp Psychiatry. May-Jun 2014;36(3):255-60. doi: 10.1016/j.genhosppsych.2013.12.007. Epub 2013 Dec 24.

27. Cozzolongo R, Porcelli P, Cariola F, et al. Serotonin gene polymorphisms and lifetime mood disorders in predicting interferoninduced depression in chronic hepatitis C. J Affect Disord. 2015 Sep 1;183:90-7. doi: 10.1016/j.jad.2015.04.056. Epub 2015 May 9.

28. Kraus MR, Schäfer A, Schöttker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut. 2008 Apr;57(4):531-6. doi: 10.1136/gut.2007.131607. Epub 2007 Dec 13.

29. Cunha ECM, Behrensdorf MF, Bavaresco V, et al. Genotype 1 of hepatitis C virus increases the risk of major despession: a 12 week prospective study. Gen Hosp Psychiatry. Jul-Aug 2015;37(4):283-7. doi: 10.1016/j.genhosppsych.2015.03.016. Epub 2015 Mar 31.

30. Whale R, Fialho R, Rolt M, et al. Psychomotor retardation and vulnerability to interferon alpha induced major depressive disorder: Prospective study of a chronic hepatitis C cohort. J Psychosom Res. 2015 Dec;79(6):640-5. doi: 10.1016/j.jpsychores.2015.06.003. Epub 2015 Jun 18.

31. Hamad T. Relationship between psychotropic drugs and pediatric suicidality: review and evaluation of clinical data. Available from: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065bl-10-TAB08-Hammads-Review.pdf (accessed 2020 May 19).

32. Yudofsky SC. β-Blockers and Depression: The Clinician's Dilemma. JAMA. 1992 Apr 1;267(13):1826-7. doi: 10.1001/jama.1992.03480130142042

33. Pedrol E, Llibre JM, Tasias M, et al. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study. HIV Med. 2015 Nov;16(10):628-34. doi: 10.1111/hiv.12298. Epub 2015 Aug 4.

34. Zdilar D, Franco-Bronson K, Buchler N, et al. Hepatitis C, interferon alfa, and depression. Hepatology. 2000 Jun;31(6):1207- 11. doi: 10.1053/jhep.2000.7880

35. Victoroff JI, Benson F, Engel J, et al. Interictal depression in patients with medically intractable complex partial seizures: electroencephalography and cerebral metabolic correlates. Ann Neurol. 1990;28:221.

36. Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry. 2002 Mar;63(3):194-8. doi: 10.4088/jcp.v63n0304

37. Hauser P, Khosla J, Aurora H, et al A prospective study of the incidence and openlabel treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7(9):942-7. doi: 10.1038/sj.mp.4001119

38. Chen WC, Lai HC, Su WP, et al. Bupropion for interferon-alpha-induced depression in patients with hepatitis C viral infection: an open-label study. Psychiatry Investig. 2015 Jan;12(1):142-5. doi: 10.4306/pi.2015.12.1.142. Epub 2015 Jan 12.

39. Camacho A, Ng B. Methylphenidate for alpha-interferon induced depression. J Psychopharmacol. 2006 Sep;20(5):687-9. doi: 10.1177/0269881106063134. Epub 2006 Mar 13.

40. Malek-Ahmadi P, Prabhu F. Venlafaxine for treatment of interferon alfa-induced depression. Ann Pharmacother. 2006 Nov;40(11):2075. doi: 10.1345/aph.1H133. Epub 2006 Oct 17.

41. Patten SB. Psychopharmacology for the clinician psychopharmacologie pratique. J Psychiatry Neurosci. 2001 Jan;26(1):66.

42. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry. 1989 Jul;50(7):256-61.

43. Lambert MV, Robertson MM. Depression in epilepsy: etiology, phenomenology, and treatment. Epilepsia. 1999;40 Suppl 10:S21- 47. doi: 10.1111/j.1528-1157.1999.tb00884.x

44. Sabet-Sharghi F, Hutzler JC. Prophylaxis of steroid-induced psychiatric syndromes. Psychosomatics. Winter 1990;31(1):113-4. doi: 10.1016/S0033-3182(90)72233-5

45. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001 Mar 29;344(13):961-6. doi: 10.1056/NEJM200103293441303

46. Ehret M, Sobieraj DM. Prevention of interferon-alpha-associated depression with antidepressant medications in patients with hepatitis C virus: a systematic review a nd meta-analysis. Int J Clin Pract. 2014 Feb;68(2):255-61. doi: 10.1111/ijcp.12268. Epub 2013 Dec 22.

47. Hou XJ, Xu JH, Wang J, Yu YY. Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials? PLoS One. 2013 Oct 30;8(10):e76799. doi: 10.1371/journal.pone.0076799. eCollection 2013.

48. Udina M, Hidalgo D, Navines R, et al. Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry. 2014 Oct;75(10):e1113-21. doi: 10.4088/JCP.13r08800


For citation:


Ebzeeva E.Yu., Ostroumova O.D., Batyukina S.V., Ostroumova T.M., Kochetkov A.I., Kirichenko A.A. Drug-induced (medication-induced) depression in neurology practice. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(2):104-110. (In Russ.) https://doi.org/10.14412/2074-2711-2021-2-104-110

Views: 117


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)